Forte Biosciences, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026A merger means the company is being bought, which changes what shareholders own and when they get paid.
Study results show if the drug works, which determines if the company can make money selling it in the future.
The company is preparing to raise money by selling stock, which dilutes existing shareholders' ownership.
More shares are reserved for employee stock options, which means future dilution for existing shareholders.
Quarterly earnings show if the business is making progress toward profitability or spending down cash.
The company raises $141 million but existing shareholders' ownership gets diluted by the new shares.
Stocky reads Forte Biosciences, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Forte Biosciences, Inc.'s most recent tracked filing was a 8-K on 27 Jul 2026: Company entering merger agreement with Parent and Purchaser.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.